Corbus Pharmaceuticals’ Post

Very excited to be at the Society for Immunotherapy of Cancer (SITC) annual meeting to present new preclinical data for casdozokitug, a first-in-class IL-27 antibody. The poster highlights the IFN signaling-like properties of IL-27 and importantly describes biomarkers that may be useful for evaluating cancer patient treatment with casdozokitug. View the poster: https://bit.ly/3Mti9UU #SITC2023

A recently published study by Merck KGaA, Darmstadt, Germany, EMD Serono, Inc., Christian-Albrechts-Universität zu Kiel, and Technische Universität Darmstadt investigates bispecific NK cell-engaging antibodies (NKCEs) for cancer immunotherapy, focusing on the impact of antibody architecture on their efficacy. ✅ It highlights the importance of design, valency, and NKp30 epitope recognition in influencing NKCE characteristics. ✅ The research emphasizes the benefits of Fc domains for prolonged half-life and demonstrates that the tested NKCEs exhibit IgG-like pharmacokinetic profiles, indicating their clinical potential in cancer treatment. ✅ For simultaneous binding experiments as well as kinetic measurements the Octet®️ BLI technology was used. Read the study here: https://ow.ly/mzfO50RE5fG #AntibodyEngineering #ProteinEngineering #Antibodies #DrugDevelopment #EpitopeMapping #OctetBLI

#ACROHighlights [Featured Product] As CD3 is closely related to the activation of T cells, CD3-targeting BsAb is an emerging therapeutic modality in cancer immunotherapy. To accelerate the research and development of CD3-BsAb, ACROBiosystems has developed a series of homogeneous CD3δ/CD3ε and CD3γ/CD3ε proteins with high bioactivity, which can be used in applications including, but not limited to clinical pharmacokinetics, therapeutic antibody screening, identification, and characterization. Learn More: https://smpl.is/7z0fw #CancerImmunotherapy #CD3BsAb

A game-changing new way to treat intractable (primarily solid tumour, e.g. prostate) cancers is emerging in the advanced therapy space. Novartis is the first to achieve regulatory approval for PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) HCP and #Lutathera. However the supply chain logistics are exceedingly difficult as the therapy is actively undergoing radioactive decay, which necessitates special licenses and risk mitigation to avoid loss of material and exposure. Will be interesting to see how this field evolves and who will be defining the supply chain aspects as more of them become approved and available to patients. #radioligandtherapy Also check out this patient story to understand the impact this has to patient quality of life: https://lnkd.in/gP9dRhnc

Extensive Stage Small Cell Lung Cancer Market to Record an Exponential CAGR by 2031 - Exclusive Report by InsightAce Analytic: JERSEY CITY, N.J., Dec. 13, 2023 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global Extensive Stage Small Cell Lung Cancer Market By Products (Commercial, Clinical), Market Outlook and Industry Analysis 2031" According to...

In November 2023, our CMO, Dr. Qasim Iftikhar Ahmad, participated in Drug Discovery World's Turning Science into Business Summit, focusing on 'cancer research opportunities and advances' and 'cutting-edge concepts and tools in cancer drug discovery'.   During his presentation, Dr. Ahmad delved into IO Biotech's novel immunotherapy approach and its lead investigational therapeutic cancer vaccine candidate, IO102-IO103, with a dual mechanism of action designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment, which is currently being evaluated in a pivotal Phase 3 study for the first line treatment of patients with advanced #melanoma.   Read more on page 10 in Drug Discovery World's Winter 2023/2024 issue here: bit.ly/3S6FA8A.

The development of antibody drug conjugates (ADCs) presents a promising alternative to traditional chemotherapy for cancer treatment. By targeting cancer cells specifically, these drugs offer the potential to reduce severe side effects and improve effectiveness. Though widespread adoption may take time, ongoing advancements suggest a future where ADCs play a central role in cancer care.</div><div class="read-more"><a href="" class="more-link">Continue reading</a>https://lnkd.in/gu9SsF4U

Antibody drug conjugates (ADCs) are revolutionizing the treatment landscape for cancer by targeting specific proteins on the surface of cancer cells and delivering a toxic payload directly to the tumor. The accelerated development of ADCs in recent years reflects the industry’s heighted interest in this groundbreaking approach and commitment to advance precision medicine. This Cancer Discovery article explores the surge of investments in ADCs, including perspectives from our CEO Kenneth Galbraith about Zymeworks’ approach to highly differentiated ADC therapeutics. Read here: https://lnkd.in/e63wNiij

Reimagining cancer care with radioligand therapy (RLT) for patients with advanced cancers

🌐rizochem.com | rizochem.ae Thousands of men to participate in UK trial for prostate cancer. A new clinical trial is set to begin in the UK that will test the effectiveness of a new drug for prostate cancer. The trial will involve over 5,000 men aged 50 and over who have been diagnosed with early-stage prostate cancer. The drug, which is called relutamid, has been shown in previous studies to reduce the risk of the cancer spreading or returning. If the trial is successful, relutamid could become a new standard of care for men with prostate cancer. #health #science #pharmacy #rx #pharmacytech